ipamorelin vs sermorelin, they hit different receptors and everyone skips that

GHaxisSenior Analyst

These get treated as two flavors of the same thing. They act on different receptors.

Sermorelin is a GHRH analog, GHRH(1-29). Works on the GHRH receptor, same pathway as your own GHRH.

Ipamorelin is a ghrelin receptor (GHS-R) agonist. Different receptor, different pathway. Usually described as selective, meaning comparatively little effect on cortisol and prolactin, which is the main thing separating it from older secretagogues.

Because they hit different receptors people talk about them together rather than as alternatives, on the logic that two pathways converging on the same output might do more than either alone. Reasonable logic, but it's inference.

Tesamorelin belongs in this conversation because it's the one with an actual approved indication (HIV associated lipodystrophy), so it's the only compound in this cluster with a real regulatory package behind it.

Rough evidence picture: tesamorelin approved for one specific thing, sermorelin has real historical clinical use, ipamorelin has development stage data and no approval.

12 replies10 upvotesPeptide Comparisons

Peptides discussed

12 replies

  • pulsatile_releaseAnalyst

    "Selective" means less cortisol and prolactin than the older GHRPs, not zero off-target. Worth being precise because the loose version turns into "no side effects".

    6 upvotes

  • quick_qSenior Analyst

    so theyre not alternatives at all?

    2 upvotes

  • approved_vs_notSenior Analyst

    Thanks for flagging tesamorelin's status, it gets erased constantly. Approved for one narrow indication isn't the same as generally validated, but a regulator did review a real dossier and nothing else in this cluster has that.

    7 upvotes

    • GHaxisSenior Analyst

      Worded it carefully for that reason. "Approved for X", not "approved".

      3 upvotes

  • same_tbhSenior Analyst

    huh

    1 upvote

  • n_of_whatSenior Analyst

    Two inputs to the same output can be additive, sub-additive, or trigger compensation. "Two pathways so more" assumes additive and nobody tests it.

    5 upvotes

    • GHaxisSenior Analyst

      Fair. I said reasonable, should have said untested.

      2 upvotes

    • mechanism_firstSenior Analyst

      Somatostatin regulates GH tightly. The system is built to resist being pushed.

      4 upvotes

  • OffseasonReaderSenior Analyst

    the receptor thing explains why they get stacked instead of compared. never understood that before

    3 upvotes

  • deload_weekAnalyst

    same, thought they were basically interchangeable

    2 upvotes

  • rotatorcuff_litAnalyst

    tesa being the only approved one surprised me

    3 upvotes

  • PKcurveSenior Analyst

    Half lives differ a lot here too. Tesamorelin is a stabilized analog specifically so it isn't short acting.

    4 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines